戴维医疗(300314) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥123,508,749.78, a decrease of 9.67% compared to the same period last year[3] - Net profit attributable to shareholders was ¥203,968.11, down 99.71% year-on-year, while net profit after deducting non-recurring gains and losses was -¥3,187,310.04, a decrease of 104.80%[3] - Total operating revenue for Q3 2021 was CNY 325,808,561.28, an increase from CNY 316,668,695.71 in Q3 2020, representing a growth of approximately 3.6%[23] - Net profit for Q3 2021 was CNY 67,419,638.85, down from CNY 126,565,808.75 in Q3 2020, reflecting a decrease of approximately 46.8%[24] - Basic and diluted earnings per share decreased to CNY 0.2341 from CNY 0.4395 year-over-year, a decline of about 46.8%[24] Cash Flow and Liquidity - The net cash flow from operating activities was -¥28,803,236.80, representing a decline of 240.23% compared to the previous year[10] - Cash flow from operating activities showed a net outflow of CNY -28,803,236.80, compared to a net inflow of CNY 20,539,717.50 in the same period last year[26] - Cash and cash equivalents at the end of Q3 2021 were CNY 219,603,384.97, down from CNY 144,279,882.78 at the end of Q3 2020[28] - The company's cash and cash equivalents stood at ¥221,273,784.97, slightly down from ¥224,175,086.85 at the end of 2020[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,105,272,912.48, a decrease of 1.50% from the end of the previous year[3] - The total assets of the company as of September 30, 2021, were ¥1,105,272,912.48, down from ¥1,122,135,774.65 at the end of 2020, indicating a decrease of approximately 1.5%[20] - The company's total liabilities decreased to ¥127,533,281.79 from ¥168,615,782.81, representing a reduction of about 24.4%[20] - Total current assets amounted to ¥796,927,882.53, a decrease from ¥804,481,903.42 at the end of 2020, reflecting a decline of approximately 0.7%[19] Equity and Retained Earnings - The company's retained earnings increased to ¥445,302,365.60 from ¥421,082,726.75, showing a growth of approximately 5.7%[20] - The total equity attributable to the parent company increased to ¥977,739,630.69 from ¥953,519,991.84, representing an increase of about 2.5%[20] - Total equity attributable to shareholders was reported at ¥953,519,991.84, remaining stable compared to the previous period[33] Expenses - The company reported a significant increase in sales expenses, which rose by 62.38% to ¥70,739,120.39, mainly due to increased sales from its subsidiary[9] - Research and development expenses for Q3 2021 were CNY 27,858,075.00, compared to CNY 25,950,832.31 in Q3 2020, indicating an increase of about 7.3%[23] Accounts Receivable and Inventory - Accounts receivable increased by 88.61% to ¥28,503,546.51 due to increased credit extended to agents[8] - Inventory rose by 32.92% to ¥138,785,066.97, attributed to an increase in product variety and extended delivery times for raw materials[8] - Accounts receivable increased to ¥28,503,546.51 from ¥15,112,537.55, marking an increase of approximately 88.8%[18] - Inventory levels rose to ¥138,785,066.97, compared to ¥104,413,122.93 at the end of 2020, reflecting an increase of about 32.8%[18] Investment Income - Investment income decreased by 87.05% to ¥8,241,217.90, primarily due to significant fluctuations in the stock price of an associated company[9] - Investment income for Q3 2021 was CNY 8,241,217.90, a decrease from CNY 63,653,941.70 in Q3 2020, reflecting a decline of about 87.1%[23] Other Information - The company reported a total of 98,645,352 restricted shares, with no new restrictions added during the period[16] - The company has not undergone an audit for the third quarter report[34] - The company is implementing new leasing standards starting from 2021, which may affect future financial reporting[34] - The report indicates no adjustments or significant changes in accounting policies for the current period[34]